JP2019520355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520355A5 JP2019520355A5 JP2018566485A JP2018566485A JP2019520355A5 JP 2019520355 A5 JP2019520355 A5 JP 2019520355A5 JP 2018566485 A JP2018566485 A JP 2018566485A JP 2018566485 A JP2018566485 A JP 2018566485A JP 2019520355 A5 JP2019520355 A5 JP 2019520355A5
- Authority
- JP
- Japan
- Prior art keywords
- ded
- patient
- seq
- tnfα
- response marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 89
- 230000004044 response Effects 0.000 claims description 70
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 63
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 63
- 239000003550 marker Substances 0.000 claims description 57
- 239000005557 antagonist Substances 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 44
- 239000012472 biological sample Substances 0.000 claims description 26
- 108700028369 Alleles Proteins 0.000 claims description 21
- 238000003556 assay Methods 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 238000003752 polymerase chain reaction Methods 0.000 claims description 6
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 101710099953 DNA mismatch repair protein msh3 Proteins 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 238000000636 Northern blotting Methods 0.000 claims description 3
- 238000002105 Southern blotting Methods 0.000 claims description 3
- 238000005251 capillar electrophoresis Methods 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 238000003018 immunoassay Methods 0.000 claims description 3
- 238000003364 immunohistochemistry Methods 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 238000002731 protein assay Methods 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000001179 synovial fluid Anatomy 0.000 claims description 3
- 210000001138 tear Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 19
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 210000002784 stomach Anatomy 0.000 claims 3
- 238000003491 array Methods 0.000 claims 1
- 210000003608 fece Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022121796A JP2022169546A (ja) | 2016-06-20 | 2022-07-29 | ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352091P | 2016-06-20 | 2016-06-20 | |
| US62/352,091 | 2016-06-20 | ||
| PCT/IB2017/053625 WO2017221128A1 (en) | 2016-06-20 | 2017-06-19 | Methods of treating dry eye disease using tnf alpha antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022121796A Division JP2022169546A (ja) | 2016-06-20 | 2022-07-29 | ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520355A JP2019520355A (ja) | 2019-07-18 |
| JP2019520355A5 true JP2019520355A5 (enExample) | 2020-07-30 |
| JP7583515B2 JP7583515B2 (ja) | 2024-11-14 |
Family
ID=59285284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566485A Active JP7583515B2 (ja) | 2016-06-20 | 2017-06-19 | ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 |
| JP2022121796A Pending JP2022169546A (ja) | 2016-06-20 | 2022-07-29 | ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022121796A Pending JP2022169546A (ja) | 2016-06-20 | 2022-07-29 | ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12146187B2 (enExample) |
| EP (1) | EP3472203A1 (enExample) |
| JP (2) | JP7583515B2 (enExample) |
| CN (1) | CN109311976A (enExample) |
| CA (1) | CA3032790A1 (enExample) |
| WO (1) | WO2017221128A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7583515B2 (ja) * | 2016-06-20 | 2024-11-14 | ノバルティス アーゲー | ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 |
| CN114075597A (zh) * | 2020-08-12 | 2022-02-22 | 深圳市坪山区人民医院 | 用于sle易感基因snp检测的核酸组合物、试剂盒及其使用方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818537A (en) | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
| US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| US5958912A (en) | 1992-04-21 | 1999-09-28 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β |
| US5290572A (en) | 1992-08-06 | 1994-03-01 | Deo Corporation | Opthalmic composition for treating dry eye |
| US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| WO1997020578A1 (en) | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| CN1114401C (zh) | 1998-07-14 | 2003-07-16 | 阿尔康实验室公司 | 11－(3－二甲氨基亚丙基)－6,11－二氢二苯并[b,e]噁庚英－2－乙酸用于制药的新用途 |
| US20090098136A1 (en) * | 2007-10-15 | 2009-04-16 | Alcon Research, Ltd. | Use of tnf receptor antagonists for treating dry eye |
| ES2861592T3 (es) | 2008-06-25 | 2021-10-06 | Novartis Ag | Anticuerpos estables y solubles que inhiben el TNF |
| UY33679A (es) * | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| KR101514238B1 (ko) * | 2012-06-21 | 2015-04-28 | 한올바이오파마주식회사 | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드의 신규 용도 |
| JP7583515B2 (ja) * | 2016-06-20 | 2024-11-14 | ノバルティス アーゲー | ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 |
-
2017
- 2017-06-19 JP JP2018566485A patent/JP7583515B2/ja active Active
- 2017-06-19 EP EP17735637.5A patent/EP3472203A1/en active Pending
- 2017-06-19 WO PCT/IB2017/053625 patent/WO2017221128A1/en not_active Ceased
- 2017-06-19 US US16/311,001 patent/US12146187B2/en active Active
- 2017-06-19 CN CN201780038579.2A patent/CN109311976A/zh active Pending
- 2017-06-19 CA CA3032790A patent/CA3032790A1/en active Pending
-
2022
- 2022-07-29 JP JP2022121796A patent/JP2022169546A/ja active Pending
-
2024
- 2024-10-21 US US18/921,747 patent/US20250129414A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504430A5 (enExample) | ||
| CN103333952B (zh) | 年龄相关的黄斑变性中的遗传多态性 | |
| JP5091163B2 (ja) | 癌またはその素因の早期検出のための方法およびキット | |
| JP2017513937A5 (enExample) | ||
| JP2017519498A5 (enExample) | ||
| RU2014125071A (ru) | Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa | |
| RU2016144177A (ru) | Способы избирательного лечения астмы с использованием антагонистов il-13 | |
| CN105636648A (zh) | 用于抗tl1a疗法的系统、装置和方法 | |
| US20110189685A1 (en) | Methods of using jak3 genetic variants to diagnose and predict crohn's disease | |
| JP2017507130A5 (enExample) | ||
| SE516272C2 (sv) | Metoder och kit för analytdetektion mha proximitets-probning | |
| RU2014146594A (ru) | Способы лечения анкилозирующего спондилита с использованием антагонистов il-17 | |
| JP5676623B2 (ja) | 加齢黄斑変性における遺伝的多型性 | |
| WO2011017120A1 (en) | Use of ccr9, ccl25, batf and il17/il23 pathway variants to diagnose and treat inflammatory bowel disease | |
| JP2019520355A5 (enExample) | ||
| US20120088245A1 (en) | Methods of diagnosing insulin resistance and sensitivity | |
| AU2005271244A1 (en) | Compositions and methods for determining and predicting treatment responses for depression and anxiety | |
| US20210148910A1 (en) | Compositions and methods for treatment of atopic dermatitis and treatment selection | |
| WO2010075584A1 (en) | Methods of diagnosing and predicting crohns disease from childhood hygiene and serological profiles | |
| RU2015144019A (ru) | Биомаркеры фармакодинамического ответа опухоли | |
| EP3264087B1 (en) | Method and device for quantification of target molecules | |
| JP6494356B2 (ja) | 非アルコール性脂肪性肝疾患及び／又は非アルコール性脂肪肝炎の発症リスク及び／又は重症化リスクの判定方法、並びに該判定用オリゴヌクレオチドキット | |
| WO2022153323A1 (en) | Markers for diagnosing infections | |
| TW200940990A (en) | A diagnostic blood test for psychosis | |
| WO2005072152A2 (en) | Apoc1 genetic markers associated with age of onset of alzheimer's disease |